Jaguar Financial Announces Director Resignation

Toronto, Ontario–(Newsfile Corp. – October 22, 2018) – Jaguar Financial Corporation (TSXV: JFC) (the “Company”) announces that Mr. Martin Schultz has resigned as a director of the Company, effective immediately.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

About Jaguar Financial Corporation

Jaguar is a Canadian merchant bank that generally invests in undervalued, overlooked and underappreciated public companies where Jaguar determines that one or more changes could be made to create shareholder value.

For additional information on this press release, please contact:

Vic Alboini, Chairman & Chief Executive Officer
Jaguar Financial Corporation
416-483-3760

Advertisements

InvestmentPitch Media Video Discusses Canntab Therapeutics and its Application to Become a Licensed Producer Under ACMPR with Health Canada – Video News Alert on Investmentpitch.com

Vancouver, British Columbia–(Newsfile Corp. – October 22, 2018) –  Canntab Therapeutics (CSE: PILL) (FSE: TBF1), a Canadian cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has filed an application to become a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations with Health Canada. The License, if granted by Health Canada, would allow the company to process cannabis products at its current production facility in Markham, Ontario with minimal additional capital expenditures as compared to a new purpose-built facility.

InvestmentPitch Media has produced a “video” which provides a brief overview of this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter “Canntab” in the search box.

Cannot view this video? Visit:
http://www.investmentpitch.com/video/0_kxd7f0qt/Canntab-Therapetics-files-application-to-become-Licensed-Producer-under-ACMPR-

Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. The company’s patented technology focuses on the delivery of standardized medical cannabis extract, from selective strains, allowing medical professionals to provide pharmaceutical dosages to deliver therapeutic treatments to their patients.

Jeff Renwick, CEO of CannTab, stated: “We are excited to announce, as we enter into a new era of legalization, that Canntab has submitted its application to Health Canada to become a Licensed Producer. This is another step that enables Canntab to further diversify its manufacturing and distribution capabilities towards a world-wide rollout of its suite of precision oral dose delivery platforms for cannabis-based products.”

Canntab recently signed a non-binding Letter of Intent with NewCanna S.A.S. of Bogota, Colombia. The LOI establishes a significant bi-lateral relationship granting NewCanna the right to sell and distribute certain Canntab exclusive proprietary products, and the right to utilize Canntab’s know-how and patents in the countries of Colombia, Chile, Paraguay and Spain.

The two parties have a 60-day period to complete a formal agreement, which will trigger a one-time, non-refundable License Fee of US $2-million payable to Canntab by NewCanna in consideration for the exclusive license to be granted by Canntab to NewCanna. NewCanna would become a key supplier of raw materials for Canntab and on a cost basis which will be very favourable in comparison to other sources worldwide.

For more information, please visit the company’s website at www.canntab.ca, contact Richard Goldstein, CFO, at 416-957-6303 or email info@canntab.ca.

About InvestmentPitch Media

InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company’s story ahead of the 1,000’s of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com

InvestmentPitch Media Video Discusses Universal Ibogaine and its Addiction Treatment Program, Private Placement and Launch Event – Video Available on Investmentpitch.com

Vancouver, British Columbia–(Newsfile Corp. – October 22, 2018) – Universal Ibogaine, which is developing a diversified real estate portfolio with healthcare and detox related assets, has announced a company launch and private placement. The company’s revolutionary treatment and recovery program, using the product Ibogaine, will initially focus on the opioid epidemic in British Columbia followed by North America.

InvestmentPitch Media has produced a “video” which discusses this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter “Ibogaine” in the search box.

Cannot view this video? Visit:
http://www.investmentpitch.com/

The treatment developed and tested by Cancun, Mexico-based Clear Sky Recovery, has proven to be a superior alternative to standard treatment, medicines, and recovery centres, with success rates estimated at more than 50%. Clear Sky Recovery has successfully administered the ibogaine treatment thousands of times to its clientele including celebrities, socialites and other ultra-high-net worth individuals, for severe substance abuse disorders.

A key component of the Ibogaine treatment process is Ibogaine hydrochloride, a naturally derived substance found in the roots of the tabernanthe Iboga plant, native to west central Africa, which interrupts the process of active addiction both painlessly and rapidly. Ibogaine’s documented anti-addictive properties have successfully eradicated up to 95% of the symptoms associated with opioid withdrawal, for substances such as heroin, fentanyl, oxycontin, methadone and the full spectrum of opiate and opioid drugs.

Ibogaine is covered in a recent episode of a Netflix original Pop Doc Series produced by BuzzFeed. The program, part 2, episode 7 entitled “Rehab Tourism” features a drug addict that successfully completes the Ibogaine treatment.

Shane Nyquvest, Founder and Chairman of Universal Ibogaine, has this to say about the documentary: “We feel empowered to see that Netflix and BuzzFeed have finally brought Ibogaine treatment to mainstream media. Ibogaine is not a miracle cure, but a proven successful detox treatment. Aftercare is the key component to rehabilitation. We are building a strong infrastructure to support aftercare including our HOPE program that will empower patients to regain control of their lives with dignity. With the opioid epidemic taking lives daily I agree with Stanton’s sentiments that people are desperate, turning to detoxes in Mexico because nothing in North America has worked and that’s really the biggest problem, we are not doing enough to give the millions of people now addicted to opioids the help that they need. The time is now to save lives, the opioid epidemic is engulfing entire nations and we don’t have a moment to spare.”

Universal Ibogaine Inc. has recruited Patrick Kroupa as their President. Kroupa, an internationally-recognized ibogaine treatment expert and an early internet entrepreneur and co-founder of MindVox, was a high functioning addict who utilized ibogaine to break his own 16-year dependence on heroin and cocaine. He was subsequently recruited by the University of Miami’s, Department of Neurology, to work at their Ibogaine Research Project following FDA approval of clinical trials of ibogaine on human drug-dependent subjects in the USA. Unfortunately these studies were never completed after NIDA refused to provide further funding.

The company is currently raising gross proceeds of up to $2.5 million from a non-brokered private placement offering, available to accredited investors only, of up to 10 million units priced at $0.25 per unit with each unit consisting of one common share and one warrant, with each warrant exercisable at $0.50 for 60 months.

The company is in discussions to acquire Clear Sky Recovery and anticipates allocating funds to close this acquisition as well as acquire various real estate properties in British Columbia, which would allow the company to replicate the existing business model in North America.

The company will be holding a launch event on Tuesday October 23rd, from 4:00 to 6:00 at the Terminal City Club at 837 West Hastings Street, Vancouver, British Columbia.

For more information, please visit the company’s website www.iboquest.com, contact either Christina Rao at 604-723-7480 or by email at christina@ascensionIR.com, or Brian Gusko at 604-727-1295 or by email at brian@ascensionIR.com.

About InvestmentPitch Media

InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company’s story ahead of the 1,000’s of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com

Ivanhoe Industries: Acquisition of Common Shares of Cordoba Minerals Corp.

New York, New York–(Newsfile Corp. – October 19, 2018) – This news release is issued by Ivanhoe Industries LLC (“Ivanhoe“) pursuant to the early warning requirements of Canada’s National Instrument 62-104 and National Instrument 62-103 with respect to common shares of Cordoba Minerals Corp. (“Cordoba“).

Ivanhoe, through its affiliate, High Power Exploration Inc. (“HPX“), has subscribed for 26,605,128 units (“Units“) in Cordoba at a deemed price of C$0.0975 per Unit, for a total of US$2.0 million through non-brokered private placement (the “Placement“). Each Unit consists of one common share (“Share“) and one common share purchase warrant (“Warrant“) of Cordoba. Each Warrant will entitle the holder to purchase one Share at an exercise price of C$0.13 per Share for a period of 24 months following the closing of the Placement.

The Placement has been approved by the TSX Venture Exchange and closing occurred on October 19, 2018. The Shares and Warrants issued under the Placement will be subject to a statutory four-month hold period.

Immediately prior to the Placement, Ivanhoe Industries had beneficial ownership and control over 180,984,035 common shares representing 72.2% of the then issued and outstanding common shares of Cordoba prior to the Placement. Ivanhoe Industries now has actual beneficial ownership and control over 207,589,163 common shares representing 74.9% of the currently issued and outstanding common shares of Cordoba, and is deemed to beneficially own 32,787,439 common shares issuable upon the exercise of common share purchase warrants (including the Warrants), representing approximately 77.5% of Cordoba’s then issued and outstanding common shares on a partially diluted basis. All of these securities are beneficially owned and controlled by Ivanhoe Industries.

For further information and to obtain a copy of the early warning report filed under applicable Canadian provincial securities legislation in connection with the transactions hereunder, please go to Cordoba’s profile on the SEDAR website (www.sedar.com), or contact Penny Schattenkirk at (604) 689-8765. Ivanhoe has an office c/o 654-999 Canada Place, Vancouver, British Columbia, Canada, V6C 3E1.

Anquiro Adopts Advance Notice Policy

Vancouver, British Columbia–(Newsfile Corp. – October 19, 2018) – Anquiro Ventures Ltd.(TSXV: AQR.P) (the “Company” or “Anquiro”) announces the approval and adoption by its Board of Directors of an advance notice policy (the “Policy”). The purpose of the Policy is to provide shareholders, directors and management of Anquiro with a clear framework for nominating directors of the Company. Anquiro is committed to: (i) facilitating an orderly and efficient annual general or, where the need arises, special meeting, process; (ii) ensuring that all shareholders receive adequate notice of the director nominations and sufficient information regarding all director nominees; and (iii) allowing shareholders to register an informed vote after having been afforded reasonable time for appropriate deliberation. The Policy is intended to further these objectives.

The Policy, among other things, includes a provision that requires advance notice to the Company in certain circumstances where nominations of persons for election to the Board of Directors are made by shareholders of the Company. The Policy fixes a deadline by which director nominations must be submitted to the Company prior to any annual or special meeting of shareholders and sets forth the information that must be included in the notice to the Company. No person will be eligible for election as a director of Anquiro unless nominated in accordance with the Policy.

In the case of an annual meeting of shareholders, notice to the Company must be made not less than 30 days and not more than 65 days prior to the date of the annual meeting; provided, however, that, in the event that the annual meeting is to be held on a date that is less than 50 days after the date on which the first public announcement of the date of the annual meeting was made, notice may be made not later than the close of business on the 10th day following such public announcement.

In the case of a special meeting of shareholders called for the purpose of electing directors (whether or not called for other purposes), notice to the Company must be made not later than the close of business on the 15th day following the day on which the first public announcement of the date of the special meeting was made.

The full text of the Policy is available under the Company’s profile at www.sedar.com or upon request by contacting the Company’s Corporate Secretary at (604) 336-8611.

The Policy is in effect as at the date of this news release. Pursuant to the terms of the Policy, the Company will seek shareholder ratification of the Policy at its next annual general meeting of shareholders.

ON BEHALF OF THE BOARD

SIGNED: “Teresa Cherry

Teresa Cherry, CFO & Secretary
Contact: (604) 336-8611

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CSE New Listing – Orion Nutraceuticals Inc. Commences Trading on the Canadian Securities Exchange – Video News Alert on InvestmentPitch.com

Vancouver, British Columbia–(Newsfile Corp. – October 19, 2018) – Orion Nutraceuticals (CSE: ORI) is one of the latest new listing on the Canadian Securities Exchange. The Vancouver-based company, in conjunction with its network of sports medicine experts, is creating a line of sports medicine, CBD based, products.

InvestmentPitch Media has produced a “video” which provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter “Orion” in the search box.

Cannot view this video? Visit:
http://www.investmentpitch.com/video/0_xyyav9e7/Orion-Nutraceuticals-CSEORI-New-Listing

The company’s target market is athletes, athletic therapists, sports medicine retailers, homeopathic and pharmaceutical companies, manufacturers, distributors, wholesalers, consumers and retailers. In conjunction with its professional sports strategic alliances, the company is poised to advance research and development in the plant science sector, deliver science-based products and services to the mainstream, with proprietary brands and products.

Through its Quebec subsidiary, Medic Oasis, the company aims to become an ACMPR Licensed Producer in Quebec and is currently in Stage 5 of its Health Canada application process. Build out is expected to begin in Q1 2019, with completion of the 30,000 square foot facility expected by Q3 2019.

The company has a joint venture with Medellin-based FCM Global, Colombia’s first fully licensed producer and exporter for non-psychoactive cannabis for medical and research purposes. FCM is also in the final stages of receiving its high-THC licenses, which is anticipated in the 4th quarter of 2018. FCM Global will soon break ground on FCM Tolima, a planned 450-hectare cultivation and production site which will have production capabilities of over 1,000 tons of cannabis oil when at full capacity.

Carlos Velasquez, CEO of FCM Global, stated: “FCM congratulates Orion on achieving another significant milestone. We are proud to partner with Orion as they execute their winning formula of high-quality products plus large-scale production capacity.

Jonathan Fiteni, CEO of Orion, stated: “We are extremely excited to launch Orion Nutraceuticals as Canada celebrates the legalization of recreational cannabis. We aim to set a new standard in cannabis life science by producing and developing innovative sports medicine products with key, strategic partners in the industry. Through our partners in Colombia, FCM Global, and our domestic cannabis production facility, we intend to become the leaders in cannabis derived CBD therapies.”

For more information, please visit the company’s website at www.orionnutra.ca, contact Robin Linden, Director Investor Relations, 604-313-2768 or email investors@orionnutra.ca.

About InvestmentPitch Media

InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company’s story ahead of the 1,000’s of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com

Thornmark Alpha Fund Wins 2018 Canadian Hedge Fund Award

Toronto, Ontario–(Newsfile Corp. – October 18, 2018) – Daniel Bain, CEO & Chief Investment Officer of Thornmark Asset Management (“Thornmark”), is pleased to announce that the Thornmark Alpha Fund (the “Alpha Fund”) received an Alternative IQ’s 2018 Canadian Hedge Fund Award (“CHFA). This year is the first time the Alpha Fund entered the Alternative IQ award program. The Alpha Fund placed 3rd in the Equity Focused 5 Year Sharpe Ratio award.

Mr. Bain commented, “The Sharpe ratio measures risk-adjusted performance. We are pleased Thornmark has been recognized for performance leadership. This award further validates Thornmark’s tactical investing.”

The Canadian Hedge Fund Awards, the highest honour in Canada’s hedge fund industry, were presented yesterday evening at a Gala Dinner hosted by KPMG LLP at One King West Hotel in Toronto with 145 guests in attendance.

About Canadian Hedge Fund Awards

The Canadian Hedge Fund Awards help investors identify the most exceptional hedge funds. A total of 207 Canadian hedge funds participated in the 2018 CHFA program. The awards are based solely on quantitative performance data to June 30th, with Fundata Canada managing the collection and tabulation of the data to determine the winners. There is no nomination process or subjective assessment in identifying the winning hedge funds.

About Thornmark

With over 25-years of experience, Thornmark is a North American tactical investment manager for individuals and institutions. Tactical investing at Thornmark is designed to both grow and protect wealth. For more information, please visit us at www.thornmark.com.

Daniel L. Bain
CEO & Chief Investment Officer
(416) 204-6211
dbain@thornmark.com

Figure 1. The Alpha Fund placed 3rd in the Equity Focused 5 Year Sharpe Ratio award.

If you can’t view Figure 1, please visit:
https://orders.newsfilecorp.com/files/6131/40443_a1539809040944_98.jpg